Summary

Lung cancer morbidity and mortality remains high in the United States and beyond despite major changes over the past few years in early detection and treatment for advanced disease. Dr. Douglas E. Wood, from the University of Washington in Seattle, moderates a roundtable discussion with prominent lung cancer surgeons—Drs. Shanda H. Blackmon, Lisa M. Brown, and Mitchell J. Magee—who explain how results from the recent NELSON study are game-changing, ways to improve access to screening, how vaping is creating a new generation of cigarette smokers, and advances in systemic therapy and immunotherapy for lung cancer.